CFO SpotlightsCareers of chief financial officers, from the filings. Records as of October 28, 2026
  1. CFO Spotlights
  2. Profiles
  3. Keith Regnante

Profile

Keith Regnante

Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer), Keros Therapeutics, Inc.

Former. First published here October 28, 2026; built from records as of October 28, 2026.

Keros Therapeutics, Inc. named Annita Tanini to succeed Keith Regnante on an interim basis, effective August 4, 2026.2

Seats

The seat in the record

CompanyTitle as filedStandingFilings
Keros Therapeutics, Inc. (KROS)
Pharmaceutical Preparations
Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)Former2

Company names link to the company's page in the record at CFO Tribune, which holds the seat history.

The record

Filing by filing, latest first

  1. August 4, 2026effective

    Keros Therapeutics, Inc. named Annita Tanini to succeed Keith Regnante on an interim basis, effective August 4, 2026. Profile of Annita Tanini.

    On July 17, 2026, Keith Regnante resigned from his role as Chief Financial Officer of Keros Therapeutics, Inc. (the “Company”), effective August 3, 2026 (the “Separation Date”), to pursue other opportunities.

    [2] Filing by Keros Therapeutics, Inc., filed with the SEC on July 22, 2026. Read the filing. The record at CFO Tribune.

  2. March 4, 202610-K filed

    Keith Regnante signed the annual report of Keros Therapeutics, Inc. on Form 10-K as Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer), filed March 4, 2026.

    /s/ Keith Regnante Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

    [1] Annual report on Form 10-K by Keros Therapeutics, Inc., filed with the SEC on March 4, 2026. Read the filing. The record at CFO Tribune.

Sources

Sources

  1. Annual report on Form 10-K, Keros Therapeutics, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed March 4, 2026. sec.gov; record.
  2. Current report filed with the SEC, Keros Therapeutics, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed July 22, 2026. sec.gov; record.

Corrections and removal

If a line here is wrong, or Keith Regnante wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.